We conclude that inhibition of HSP27 alone, or in combination with pAKT inhibitor IV, may be valuable therapeutic approaches to inhibit SPARC-induced glioma cell invasion and survival in SPARC-positive/PTEN-wildtype or SPARC-positive/PTEN-null tumors, respectively. This evidence concerns the gene SPARC and central nervous system cancer.